Novo Nordisk CEO to Outline Strategy Beyond Weight-Loss Drugs Amid Competition
Audio narration · Coming soon
Novo Nordisk's CEO Mike Doustdar is expected to address the company's future strategy on Monday, focusing on how to compete with US rival Eli Lilly. The discussion will also cover plans to expand growth beyond the success of the weight-loss drug Wegovy. This comes amid increasing pressure to diversify the company's portfolio.
Why this matters
PRISM scored this story 55/100 for interest.
Originally published by gnews